Results From Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Results from this phase 1/2 trial show that single-agent tagraxofusp, a novel CD123 targeted therapy currently FDA approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, may be efficacious and safe in patients with intermediate-/high-risk relapsed/refractory myelofibrosis who have already received therapy with or cannot tolerate JAK inhibitors.

Journal of Clinical Oncology (ASCO 2019 Abstract)